Filing Flows › Utah Medical Products (UTMD) › Q1 2026 › vs Q4 2025
Utah Medical Products (UTMD) Q1 2026 vs Q4 2025 (quarter over quarter)
Utah Medical Products's revenue fell $322K (-4%) from $9.0M in Q4 2025 to $8.7M in Q1 2026. Gross margin 60.6% against 58.2% (+2.4 pts).
Utah Medical Products, Q1 2026: revenue $8.7M (-10% year over year), operating margin 29.4%, net earnings $2.6M, operating cash flow $3.1M. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Gross margin | 60.6% | 58.2% | +2.4 pts |
| Operating margin | 29.4% | 27.0% | +2.4 pts |
| Net margin | 29.9% | 28.4% | +1.5 pts |
| Free cash flow margin | 34.2% | 37.2% | -3.1 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.7M | $9.0M | −$322K | -4% |
| Gross profit | $5.3M | $5.3M | $18K | +0.3% |
| Cost of revenue | $3.4M | $3.8M | −$340K | -9% |
| Other income, net | $617K | $665K | −$48K | -7% |
| Operating profit | $2.6M | $2.4M | $124K | +5% |
| Operating expenses | $2.7M | $2.8M | −$106K | -4% |
| Pre-tax earnings | $3.2M | $3.1M | $76K | +2% |
| Research & development | $154K | $212K | −$58K | -27% |
| Net earnings | $2.6M | $2.6M | $39K | +2% |
| Income tax | $578K | $540K | $38K | +7% |
| Depreciation & amortization | $673K | $745K | −$72K | -10% |
| Share-based compensation | $120K | $111K | $9K | +8% |
| Working capital & other | $288K | −$56K | $344K | — |
| Operating cash flow | $3.1M | $3.5M | −$368K | -11% |
| Free cash flow (OCF − capex) | $3.0M | $3.4M | −$389K | -12% |
| Capital expenditures | $130K | $109K | $21K | +19% |
Questions
How much did Utah Medical Products's revenue grow quarter over quarter in Q1 2026?
Utah Medical Products's revenue fell $322K (-4%) from $9.0M in Q4 2025 to $8.7M in Q1 2026. Gross margin 60.6% against 58.2% (+2.4 pts).